Company news

Cardiff Oncology, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

February 28, 2024

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

February 28, 2024

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

February 28, 2024

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

February 25, 2024

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

February 21, 2024

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

January 16, 2024

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

November 19, 2023

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

November 1, 2023

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

October 25, 2023

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

September 25, 2023

Cardiff Oncology to Present at Upcoming Investor Conferences in September

September 4, 2023

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

August 8, 2023

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

August 6, 2023

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

May 3, 2023

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer

March 27, 2023

Cardiff Oncology Formally Introduces Scientific Advisory Board

March 5, 2023

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 1, 2023

Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference

February 26, 2023

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

February 1, 2023

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference

January 9, 2023

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

November 7, 2022

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

November 2, 2022

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

September 11, 2022

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

September 9, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022

September 5, 2022

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022

August 28, 2022

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates

August 3, 2022

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022

July 4, 2022

Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference

May 16, 2022

Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates

May 4, 2022

Cardiff Oncology Announces Departure of Chief Medical Officer

April 11, 2022

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

April 7, 2022

Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models

April 7, 2022

Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC

March 21, 2022

Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting

March 7, 2022

Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference

February 28, 2022

Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights

February 23, 2022

Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference

January 19, 2022

Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

January 17, 2022

Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs

January 10, 2022

Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

January 9, 2022

Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium

December 9, 2021

Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 2, 2021

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

November 17, 2021

Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences

November 8, 2021

Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates

November 3, 2021

Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

September 7, 2021

Cardiff Oncology to Present New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer on September 8, 2021

August 24, 2021

Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates

August 4, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 89 decks. Every deck is listed under its year.